Skip to content

Author

A. Toga

We have 5 of 302 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

White Matter Slow-4 fALFF as a Complementary Marker in the Multimodal Alzheimer’s Disease Biomarker Landscape

INTRODUCTION White matter (WM) functional activity, quantified as slow-4 fractional amplitude of low-frequency fluctuations (fALFF; 0.027–0.073 Hz), may reflect Alzheimer’s disease (AD) pathology, but its utility relative to established structural imaging markers remains poorly characterized. METHODS We analyzed 369 AD...

Ya-Li Huang, A. Toga, Lu Zhao · 0 citations
Open access Sep 2026

Astrocyte reactivity identifies p-tau217-positive individuals at elevated risk of cognitive decline across the Alzheimer’s disease continuum

It is shown that elevated plasma GFAP significantly modulates the association between p-tau217 and both cross-sectional cognitive severity and longitudinal clinical decline, and support that astrocyte reactivity is associated with greater cognitive impairment and faster clinical decline among individuals with elevated...

B. Bellaver, G. Povala, P. C. L. Ferreira et al. · 0 citations
Open access Aug 2026

EOAD-Signature Atrophy Predicts Dementia in Early-Onset MCI due to Alzheimer Disease

Findings support the potential value of EOAD-signature atrophy as an MRI-based biomarker for individualized prognostication and clinical trial stratification and support the potential value of EOAD-signature atrophy as an MRI-based biomarker for individualized prognostication and clinical trial stratification.

T. Paranhos, Yuta Katsumi, M. Brickhouse et al. · 0 citations
Open access Aug 2026

Diabetes and neurodegeneration in cognitively unimpaired older adults: implications for cognition.

Diabetes-related cortical thinning in cognitively unimpaired older adults follows a regional pattern independent of Alzheimer's and cerebrovascular pathology and partially mediates accelerated decline in processing speed, suggesting chronic hyperglycemia may contribute to diabetes-related neurodegeneration, regardless...

A. Tsiknia, Victoria R. Tennant, Marylan Davison et al. · 1 citation
Open access Sep 2026

CSF proteomics and machine learning reveal distinct stages across the Alzheimer’s disease continuum

These findings uncover protein signatures that reflect underlying AD biology and provide a foundation for stage-specific biomarkers and therapeutic targeting, with important implications for patient stratification and personalized intervention strategies.

Saima Rathore, E. Dammer, Anantharaman Shantaraman et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.